Analyst Price Target is $1.25
▲ +56.25% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for BeyondSpring in the last 3 months. The average price target is $1.25, with a high forecast of $1.25 and a low forecast of $1.25. The average price target represents a 56.25% upside from the last price of $0.80.
Current Consensus is
The current consensus among 0 polled investment analysts is to n/a stock in BeyondSpring. This N/A consensus rating has held steady for over two years.
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.